Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,760,199
  • Shares Outstanding, K 74,863
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,500 K
  • 60-Month Beta 0.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.15
  • Number of Estimates 6
  • High Estimate -1.12
  • Low Estimate -1.20
  • Prior Year -0.65
  • Growth Rate Est. (year over year) -76.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.72 +0.41%
on 02/21/20
45.04 -18.14%
on 02/10/20
-6.17 (-14.34%)
since 01/21/20
3-Month
23.86 +54.53%
on 12/06/19
45.04 -18.14%
on 02/10/20
+8.35 (+29.28%)
since 11/21/19
52-Week
13.80 +167.17%
on 02/28/19
45.04 -18.14%
on 02/10/20
+23.06 (+166.98%)
since 02/21/19

Most Recent Stories

More News
Applied Research Works Announces an Innovative Approach to the Annual Wellness Visit and PAF

Cozeva (Cozeva.com), a provider of software solutions to health systems, announced an innovative approach to submitting the Annual Wellness Visit (AWV) and Practitioner Assessment Form (PAF) in Cozeva's...

APLS : 36.87 (-5.32%)
ASTM International Approves New Production Pathway for Sustainable Aviation Fuel

Applied Research Associates, Inc. (ARA) and Chevron Lummus Global LLC (CLG) are working toward a more sustainable future by developing novel solutions to meet the global need for sustainable aviation fuels....

APLS : 36.87 (-5.32%)
Applied Research Works announces Cozeva Bridge so Providers can focus on addressing 'Real' Care Gaps

Applied Research Works, Inc. (cozeva.com) announced today Cozeva Bridge, a new service in Cozeva that consolidates medical information and incentives from health care provider groups and insurers into...

APLS : 36.87 (-5.32%)
ARA Acquires the Consulting Division of Dynatest North America

Applied Research Associates, Inc. (ARA) is pleased to announce the acquisition of the Consulting Division of Dynatest North America, a leader in pavement engineering services, as of February 3.

APLS : 36.87 (-5.32%)
Zentiva Celebrates The Parc's Impressive Scientific Track Record in 2019

Zentiva welcomed The Pharmaceutical Applied Research Center (The Parc) to their Prague headquarters to celebrate the first anniversary of The Parc Awards. The Parc is a unique research platform designed...

APLS : 36.87 (-5.32%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of an equity award to a new employee...

APLS : 36.87 (-5.32%)
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of its previously announced underwritten public offering of...

APLS : 36.87 (-5.32%)
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public offering of 9.5 million shares of...

APLS : 36.87 (-5.32%)
NLP--Just Another Acronym in the Healthcare Alphabet Soup?

Everyone knows Cozeva identifies members with potential suspects and care gaps and presents them to the provider, prompting them to take action. But did you know Cozeva now uses Natural Language Processing...

APLS : 36.87 (-5.32%)
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

A low-key week for the biotech sector, with a few pipeline and regulatory updates.

LIFE : 4.27 (-2.29%)
INCY : 80.89 (-2.27%)
EXEL : 21.09 (-1.82%)
APLS : 36.87 (-5.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade APLS with:

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the...

See More

Key Turning Points

2nd Resistance Point 40.32
1st Resistance Point 38.59
Last Price 36.87
1st Support Level 35.93
2nd Support Level 35.00

See More

52-Week High 45.04
Last Price 36.87
Fibonacci 61.8% 33.11
Fibonacci 50% 29.42
Fibonacci 38.2% 25.73
52-Week Low 13.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar